Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

Fotios Loupakis, Herbert I. Hurwitz, Leonard Saltz, Dirk Arnold, Axel F Grothey, Quynh Lan Nguyen, Stuart Osborne, Jonathan Talbot, Stefanie Srock, Heinz Josef Lenz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented. Methods: Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively. Results: Sidedness was determined in 1590 (27% right and 73% left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95% CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95% CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95% CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95% CI 0.74, 0.98; p = 0.028). Conclusions: This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.

Original languageEnglish (US)
Pages (from-to)1451-1455
Number of pages5
JournalBritish Journal of Cancer
Volume119
Issue number12
DOIs
StatePublished - Dec 11 2018

Fingerprint

Colorectal Neoplasms
Drug Therapy
Neoplasms
Disease-Free Survival
Bevacizumab
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Loupakis, F., Hurwitz, H. I., Saltz, L., Arnold, D., Grothey, A. F., Nguyen, Q. L., ... Lenz, H. J. (2018). Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 119(12), 1451-1455. https://doi.org/10.1038/s41416-018-0304-6

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. / Loupakis, Fotios; Hurwitz, Herbert I.; Saltz, Leonard; Arnold, Dirk; Grothey, Axel F; Nguyen, Quynh Lan; Osborne, Stuart; Talbot, Jonathan; Srock, Stefanie; Lenz, Heinz Josef.

In: British Journal of Cancer, Vol. 119, No. 12, 11.12.2018, p. 1451-1455.

Research output: Contribution to journalArticle

Loupakis, F, Hurwitz, HI, Saltz, L, Arnold, D, Grothey, AF, Nguyen, QL, Osborne, S, Talbot, J, Srock, S & Lenz, HJ 2018, 'Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer', British Journal of Cancer, vol. 119, no. 12, pp. 1451-1455. https://doi.org/10.1038/s41416-018-0304-6
Loupakis, Fotios ; Hurwitz, Herbert I. ; Saltz, Leonard ; Arnold, Dirk ; Grothey, Axel F ; Nguyen, Quynh Lan ; Osborne, Stuart ; Talbot, Jonathan ; Srock, Stefanie ; Lenz, Heinz Josef. / Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. In: British Journal of Cancer. 2018 ; Vol. 119, No. 12. pp. 1451-1455.
@article{e656de4e96b0432693b4acf234015049,
title = "Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer",
abstract = "Background: Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented. Methods: Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively. Results: Sidedness was determined in 1590 (27{\%} right and 73{\%} left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95{\%} CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95{\%} CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95{\%} CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95{\%} CI 0.74, 0.98; p = 0.028). Conclusions: This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.",
author = "Fotios Loupakis and Hurwitz, {Herbert I.} and Leonard Saltz and Dirk Arnold and Grothey, {Axel F} and Nguyen, {Quynh Lan} and Stuart Osborne and Jonathan Talbot and Stefanie Srock and Lenz, {Heinz Josef}",
year = "2018",
month = "12",
day = "11",
doi = "10.1038/s41416-018-0304-6",
language = "English (US)",
volume = "119",
pages = "1451--1455",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

AU - Loupakis, Fotios

AU - Hurwitz, Herbert I.

AU - Saltz, Leonard

AU - Arnold, Dirk

AU - Grothey, Axel F

AU - Nguyen, Quynh Lan

AU - Osborne, Stuart

AU - Talbot, Jonathan

AU - Srock, Stefanie

AU - Lenz, Heinz Josef

PY - 2018/12/11

Y1 - 2018/12/11

N2 - Background: Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented. Methods: Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively. Results: Sidedness was determined in 1590 (27% right and 73% left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95% CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95% CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95% CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95% CI 0.74, 0.98; p = 0.028). Conclusions: This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.

AB - Background: Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented. Methods: Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively. Results: Sidedness was determined in 1590 (27% right and 73% left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95% CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95% CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95% CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95% CI 0.74, 0.98; p = 0.028). Conclusions: This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.

UR - http://www.scopus.com/inward/record.url?scp=85057459266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057459266&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0304-6

DO - 10.1038/s41416-018-0304-6

M3 - Article

C2 - 30487637

AN - SCOPUS:85057459266

VL - 119

SP - 1451

EP - 1455

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -